<DOC>
	<DOCNO>NCT01017874</DOCNO>
	<brief_summary>The purpose study compare two different approach treat non-small cell lung cancer ( NSCLC ) East Asian never-smoker participant . Half participant receive chemotherapy ( pemetrexed/cisplatin ) follow oral anti-cancer agent ( gefitinib ) half participant receive oral anti-cancer agent ( gefitinib ) .</brief_summary>
	<brief_title>A Study Alimta/Cisplatin/Gefitinib Asian Non-smoking Participants With Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological diagnosis NSCLC locally advance metastatic disease nonsquamous histology . Participants must `` light exsmokers '' `` neversmokers '' . `` Light exsmokers '' define cease smoke great equal 5 year exceed 10 packyears . `` Neversmokers '' define smoke &lt; 100 cigarette equivalent his/her lifetime . Participants must East Asian ethnicity . No prior systemic therapy lung cancer . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Presence clinically significant ( physical exam ) thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry . Any evidence clinically active interstitial lung disease . Asymptomatic participant chronic , stable , radiographic change eligible . Participants whose Epidermal Growth Factor Receptor ( EGFR ) mutation status know prior study entry exclude . Participants EGFR mutation test perform , whose EGFR mutation status unknown inconclusive study entry eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>